Promis­ing to slim down and speed up, the ‘new’ J&J shakes up the ex­ec­u­tive com­mit­tee ahead of the big split

The new J&J has a fresh cor­po­rate face to show the pub­lic — sev­er­al in fact.

As the health­care con­glom­er­ate fol­lows a now fa­mil­iar phar­ma path in sep­a­rat­ing it­self in­to an in­no­va­tion-fo­cused R&D-based group from its less ap­peal­ing con­sumer side, it’s pro­mot­ing some key in­di­vid­u­als to the ex­ec­u­tive com­mit­tee that steers the com­pa­ny.

Those fresh faces in­clude Math­ai Mam­men, the glob­al head of R&D who joins the in­ner cir­cle as ex­ec­u­tive vice pres­i­dent of phar­ma­ceu­ti­cals, R&D. Ex­ter­nal in­no­va­tion chief Bill Hait be­comes ex­ec­u­tive vice pres­i­dent, chief ex­ter­nal in­no­va­tion, med­ical safe­ty and glob­al pub­lic health of­fi­cer. Jim Swan­son, un­til to­day sim­ply the chief in­for­ma­tion of­fi­cer, adds the EVP part to his ti­tle in mov­ing on­to the com­mit­tee. And Vanes­sa Broad­hurst, com­pa­ny group chair­man, glob­al com­mer­cial strat­e­gy or­ga­ni­za­tion, has been ap­point­ed EVP, glob­al cor­po­rate af­fairs.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE